SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Metabolic syndrome; obesity	Lacto-N-fucopentaose III (LNFPIII)	*In vitro* and mouse studies suggest LNFPIII could help treat metabolic diseases. In macrophages, LNFPIII led to greater expression of anti-inflammatory IL-10 than vehicle. In mice with high-fat diet–induced obesity and metabolic syndrome, LNFPIII prevented hepatic steatosis and increased glucose tolerance and insulin sensitivity compared with vehicle. Next steps include improving the delivery method for the glycan and determining long-term effects. *SciBX* 5(44); doi:10.1038/scibx.2012.1159 Published online Nov. 8, 2012	Patent Cooperation Treaty patent application filed; currently under option with an undisclosed company; unavailable for licensing	Bhargava, P. *et al. Nat. Med.*; published online Oct. 28, 2012; doi:10.1038/nm.2962 **Contact:** Chih-Hao Lee, Harvard School of Public Health, Boston, Mass. e-mail: clee@hsph.harvard.edu **Contact:** Donald A. Harn, The University of Georgia, Athens, Ga. e-mail: dharn@uga.edu